KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to $629.0 million.

  • Jazz Pharmaceuticals' Non-Current Deferred Tax Liability fell 2055.5% to $629.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $629.0 million, marking a year-over-year decrease of 2055.5%. This contributed to the annual value of $676.7 million for FY2024, which is 5116.08% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Non-Current Deferred Tax Liability of $629.0 million as of Q3 2025, which was down 2055.5% from $682.1 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability registered a high of $1.9 billion during Q4 2021, and its lowest value of $109.9 million during Q1 2021.
  • Its 5-year average for Non-Current Deferred Tax Liability is $979.7 million, with a median of $910.7 million in 2023.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability skyrocketed by 101184.46% in 2022 and then tumbled by 5116.08% in 2024.
  • Jazz Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $1.9 billion in 2021, then dropped by 21.52% to $1.5 billion in 2022, then decreased by 7.2% to $1.4 billion in 2023, then crashed by 51.16% to $676.7 million in 2024, then fell by 7.05% to $629.0 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $629.0 million for Q3 2025, versus $682.1 million for Q2 2025 and $670.8 million for Q1 2025.